On June 23, 2025, Passage Bio, Inc. reported positive interim data from its clinical trial for PBFT02, showing a robust increase in cerebrospinal fluid levels in patients with frontotemporal dementia, and planning a protocol amendment for safety adjustments in future cohorts.